Oncolytics Biotech Unveils Promising Pelareorep Data at ASCO 2025

An announcement from Oncolytics Biotech ( (TSE:ONC) ) is now available.

Oncolytics Biotech announced new data from its Phase I/II GOBLET clinical trial, presented at the 2025 ASCO Annual Meeting, highlighting pelareorep’s unique immune activation capabilities in treating pancreatic ductal adenocarcinoma (PDAC). The findings reveal that pelareorep can initiate a pro-inflammatory tumor microenvironment and enhance both innate and adaptive immune responses, potentially converting immunologically cold tumors into active ones. This could improve treatment outcomes when used in combination therapies, offering promising implications for stakeholders and advancing Oncolytics’ position in the oncology sector.

The most recent analyst rating on (TSE:ONC) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the TSE:ONC Stock Forecast page.

Spark’s Take on TSE:ONC Stock

According to Spark, TipRanks’ AI Analyst, TSE:ONC is a Neutral.

Oncolytics Biotech faces significant financial challenges with persistent operational losses and reliance on external funding. Although technical indicators suggest bearish momentum, clinical advancements in cancer treatments provide some optimism. The valuation reflects the speculative nature of biotech investments, with no revenue and negative P/E. Recent earnings call and corporate events offer potential upside through strategic developments but are overshadowed by leadership transitions and market value concerns. Overall, the stock remains speculative with potential upside contingent on successful clinical outcomes.

To see Spark’s full report on TSE:ONC stock, click here.

More about Oncolytics Biotech

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent for oncology. The company specializes in immunotherapy, targeting cancer treatment through innovative approaches to stimulate the immune system.

Average Trading Volume: 75,426

Technical Sentiment Signal: Sell

Current Market Cap: C$47.96M

Find detailed analytics on ONC stock on TipRanks’ Stock Analysis page.